Exelixis, Inc. financial data

Symbol
EXEL on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
1851 Harbor Bay Parkway, Alameda, CA
State of incorporation
DE
Fiscal year end
January 3
Latest financial report
10-Q - Q3 2024 - Oct 29, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 374 % -18.6%
Quick Ratio 5.31 % -37.8%
Debt-to-equity 30.6 % +25.8%
Return On Assets 16.3 % +445%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 286M shares -8.17%
Common Stock, Shares, Outstanding 286M shares -8.1%
Entity Public Float 4.7B USD -31.2%
Common Stock, Value, Issued 286K USD -8.04%
Weighted Average Number of Shares Outstanding, Basic 286M shares -9.47%
Weighted Average Number of Shares Outstanding, Diluted 291M shares -8.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 2.08B USD +17.3%
Research and Development Expense 906M USD -20.3%
Costs and Expenses 1.56B USD -10.1%
Operating Income (Loss) 523M USD +1176%
Income Tax Expense (Benefit) 133M USD +329%
Net Income (Loss) Attributable to Parent 467M USD +407%
Earnings Per Share, Basic 1.59 USD/shares +468%
Earnings Per Share, Diluted 1.57 USD/shares +481%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 258M USD -34.9%
Marketable Securities, Current 931M USD
Inventory, Net 21M USD -15.9%
Assets, Current 1.55B USD +7.37%
Deferred Income Tax Assets, Net 359M USD +55.4%
Property, Plant and Equipment, Net 124M USD +2.79%
Operating Lease, Right-of-Use Asset 233M USD -0.67%
Goodwill 63.7M USD 0%
Other Assets, Noncurrent 280M USD +108%
Assets 2.96B USD -0.56%
Accounts Payable, Current 59.3M USD +124%
Contract with Customer, Liability, Current 3.25M USD -53.4%
Liabilities, Current 394M USD +4.65%
Contract with Customer, Liability, Noncurrent 3.95M USD -38%
Operating Lease, Liability, Noncurrent 194M USD +1.88%
Other Liabilities, Noncurrent 96.1M USD +55.9%
Liabilities 685M USD +8.83%
Accumulated Other Comprehensive Income (Loss), Net of Tax 3.96M USD
Retained Earnings (Accumulated Deficit) -90.3M USD +28.4%
Stockholders' Equity Attributable to Parent 2.28B USD -3.08%
Liabilities and Equity 2.96B USD -0.56%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 68.8M USD -18.5%
Net Cash Provided by (Used in) Financing Activities -184M USD -4113%
Net Cash Provided by (Used in) Investing Activities 112M USD
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 286M shares -8.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.43M USD -109%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 258M USD -34.9%
Deferred Tax Assets, Valuation Allowance 83M USD +7.47%
Deferred Tax Assets, Gross 498M USD +37.9%
Operating Lease, Liability 216M USD +3.77%
Payments to Acquire Property, Plant, and Equipment 9.69M USD -19.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 485M USD +407%
Lessee, Operating Lease, Liability, to be Paid 316M USD -1.18%
Property, Plant and Equipment, Gross 209M USD +21.9%
Operating Lease, Liability, Current 25.7M USD +45.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 25.6M USD +8.16%
Lessee, Operating Lease, Liability, to be Paid, Year One 26.3M USD +45.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 79.3M USD -10.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 26.2M USD +13.3%
Deferred Tax Assets, Operating Loss Carryforwards 29.5M USD -12.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 116M USD +32%
Lessee, Operating Lease, Liability, to be Paid, Year Four 27M USD +14.2%
Additional Paid in Capital 2.36B USD -5.06%
Depreciation, Depletion and Amortization 6.38M USD -6.96%
Deferred Tax Assets, Net of Valuation Allowance 415M USD +46.2%
Share-based Payment Arrangement, Expense 91.8M USD -14.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%